Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719092 · ClinicalTrials.gov registry record · NA
High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant
A NA study of Allogeneic Hematopoietic Stem Cell Transplantation Recipient, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03719092: Active NA study of Allogeneic Hematopoietic Stem Cell Transplantation Recipient, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03719092 is a NA study of Allogeneic Hematopoietic Stem Cell Transplantation Recipient that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 62 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719092, a NA study of Allogeneic Hematopoietic Stem Cell Transplantation Recipient, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and how well high dose vitamin A works in preventing gastrointestinal graft versus host disease (GVHD) in participants undergoing donor stem cell transplant. Vitamin A deficiency is associated with increased risk of gastrointestinal GVHD. Vitamin A regulates growth and differentiation of intestinal cells and may reduce risk of gastrointestinal GVHD.
Primary Outcome
Determining a Vitamin A dose administered within 14 days prior to transplant that maintains level in the upper quartile of normal range for sex at day 28 (+/- 7 days) after stem cell infusion as well as tolerable in adult allogeneic stem cell transplant recipients. determining a Vitamin A dose administered within 14 days prior to transplant that maintains level in the upper quartile of normal range for sex at day 28 (+/- 7 days) after stem cell infusion as well as tolerable in adult allogeneic
Conditions Studied
Interventions
- OTHER Best Practice
- DIETARY_SUPPLEMENT Vitamin A Compound
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-02-07 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT03719092 still lists
NCT03719092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Allogeneic Hematopoietic Stem Cell Transplantation Recipient appearing as the primary indexed condition, and to 2 interventions - of which Best Practice is the first listed.
NCT03719092 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03719092 about?
NCT03719092 is a clinical study titled "High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant". This phase I trial studies the side effects and how well high dose vitamin A works in preventing gastrointestinal graft versus host disease (GVHD) in participants undergoing donor stem cell transplant. Vitamin A deficiency is associated with increased risk of gastrointestinal GVHD. Vitamin A regulat...
What is the current status of trial NCT03719092?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 62 participants. The study started on 2020-02-07. Estimated completion is 2026-12-31.
What conditions does trial NCT03719092 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient.
What interventions are being tested in trial NCT03719092?
The interventions under investigation include: Best Practice (OTHER), Vitamin A Compound (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03719092?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03719092 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03719092's enrollment target sits among peer trials
62 1157th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
-
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI